Necroptosis is a well-controlled process of programmed necrosis present in inflammatory disorders mainly regulated by RIPK1, RIPK3 and mixed-lineage kinase domain-like pseudokinase (MLKL).
Rigel Pharmaceuticals Inc. cut the biggest deal of the company’s life with its new collaboration with Eli Lilly and Co. that could be worth $960 million. The two will co-develop and commercialize Rigel’s R-552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases.